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The continuous production of biopharmaceuticals combines several advantages: the use of smaller equipment, 
faster and more efficient processing, higher volumetric productivities, as well as a more uniform product quality 
[1]. Mammalian cell perfusion cultures employing an external cell retention device have shown to support long-
term operation at very high viable cell densities with the possibility of direct integration to subsequent 
downstream steps [2] However, knowledge on time and cost effective development and scale-up procedures to 
achieve a reliable reactor operation and desired product characteristics is still limited. Therefore, this study aims 
at the definition of a comprehensive optimization framework for mammalian cell cultures utilizing a combination 
of small-scale spin tube and bench top bioreactor experiments. 
 
In a first step, rapid evaluation of suitable operating conditions in small scale simulated perfusion cultures 
allowed the identification of key process parameters to facilitate steady state operation and process control. 
Their choice was further refined in a stirred tank perfusion bioreactor setup [3] by sequential screening of steady 
states while targeting improved product yields and desired product quality characteristics. Varying one 
parameter at a time, measurements of extra- and intracellular metabolites, product concentration and quality 
attributes were used to optimize the reactor performance. Comparable growth behaviour and metabolite 
consumption/production rates were observed between experimental scales.  
 
The tuning of key cell culture parameters led to a superior performance of the perfusion culture. Especially, the 
decrease of the cell specific perfusion rate (CSPR) prevented excessive cellular growth and significantly reduced 
the loss of product in the bleed stream. Constant patterns of product quality attributes such as N-linked 
glycosylation and charge isoforms were observed within each steady state but slight varied between different 
operating points.  
 
Overall, this study underlines the potential of perfusion cultures to simultaneously achieve high productivities 
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